Advertisement

Topics

Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference

12:01 EDT 29 Jun 2017 | FinanzNachrichten

Confirmation of potential to be the first orally available substrate reduction therapy for MPS VI patients Phase IIa iMProveS clinical study scheduled to begin before year end 2017 Regulatory News...

Original Article: Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference

NEXT ARTICLE

More From BioPortfolio on "Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference"

Advertisement
Quick Search
Advertisement
Advertisement